Literature DB >> 6339292

A comparative multicentre trial of halometasone/triclosan cream and betamethasone dipropionate/gentamicin sulphate cream in the treatment of infected acute eczematous dermatitis.

H Weitgasser, C Schindléry, V Macarol.   

Abstract

A multicentre, between-patient, comparative trial was carried out to compare the efficacy and tolerability of a cream containing 0.05 halometasone and 1% triclosan with those of a cream with 0.05% betametasone dipropionate and 0.1% gentamicin sulphate in patients suffering from infected acute ezcematous dermatoses. In the evaluable trial population, consisting of 265 patients, halometasone/triclosan cream yielded a significantly (p = 0.001) higher success rate ('good' to 'very good' results), namely 96%, than the comparative cream (80%). Halometasone/triclosan cream also displayed a significantly (p = 0.008) higher cure rate (73.9%) than that observed with the comparative preparation (58.6%). The proportion of patients obtaining an early cure, i.e. in less than 20 days, was significantly (p = 0.0005) higher with halometasone/triclosan cream (42.5%) than with the comparative preparation (22.6%). The two preparations did not differ significantly with regard to the incidence and severity of adverse effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339292

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

1.  Interventions to reduce Staphylococcus aureus in the management of eczema.

Authors:  Susannah Mc George; Sanja Karanovic; David A Harrison; Anjna Rani; Andrew J Birnie; Fiona J Bath-Hextall; Jane C Ravenscroft; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-10-29

Review 2.  Triclosan: An Update on Biochemical and Molecular Mechanisms.

Authors:  Mohammad A Alfhili; Myon-Hee Lee
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

3.  Evaluation of Efficacy, Safety, and Tolerability of Fixed Dose Combination (FDC) of Halometasone 0.05% and Fusidic Acid 2% W/W Topical Cream Versus FDC of Betamethasone Valerate 0.12% and Neomycin Sulphate 0.5% W/W Topical Cream in the Treatment of Infected Eczematous Dermatosis in Indian Subjects: A Randomized Open-Label Comparative Phase III Multi-Centric Trial.

Authors:  Dasiga Venkata Subrahmanya Pratap; Mariam Philip; Narayana T Rao; Hemangi R Jerajani; Sainath A Kumar; Maria Kuruvila; Latha S Moodahadu; Shilpi Dhawan
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.